- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- Interventions
- AMG 420
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Park Ridge, Illinois • Boston, Massachusetts • New York, New York + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 30
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
- Interventions
- Evolocumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more
- Conditions
- Hypercholesterolemia
- Interventions
- Evolocumab, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 970 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 59
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more
- Conditions
- Obesity
- Interventions
- AMG 598, Placebo, Liraglutide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Tustin, California • South Miami, Florida + 1 more
- Conditions
- Severe Familial Hypercholesterolemia
- Interventions
- Evolocumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New York, New York • Cincinnati, Ohio + 1 more
- Conditions
- Chronic Migraine or Episodic Migraine
- Interventions
- Placebo, AMG 301
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 21
- States / cities
- Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- AMG 570, AMG 570 Matching Placebo
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Evansville, Indiana • Overland Park, Kansas • Madison, Wisconsin
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Placebo to Evolocumab
- Biological · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 631 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Malvern, Arkansas + 48 more
- Conditions
- Hyperlipidemia and Mixed Dyslipidemia
- Interventions
- Evolocumab, Standard of Care
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 3,681 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
- Conditions
- Hypercholesterolemia
- Interventions
- Evolocumab, Standard of care
- Biological · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more
- Conditions
- Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes
- Interventions
- Evolocumab, Placebo to Evolocumab
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 46
- States / cities
- Tuscumbia, Alabama • Phoenix, Arizona • Lomita, California + 39 more
- Conditions
- Hypercholesterolemia
- Interventions
- Evolocumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 770 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 24
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Long Beach, California + 21 more
- Conditions
- Dyslipidemia
- Interventions
- Evolocumab, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 27,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 326
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 275 more
- Conditions
- Diabetes, Hyperlipidemia, Mixed Dyslipidemia
- Interventions
- Evolocumab, Atorvastatin, Placebo
- Biological · Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 11
- States / cities
- Miami, Florida • Atlanta, Georgia • Indianapolis, Indiana + 8 more
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2,067 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Placebo to Evolocumab, Ezetimibe, Placebo to Ezetimibe
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 20
- States / cities
- Carmichael, California • Los Angeles, California • Mission Viejo, California + 15 more
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Ezetimibe, Placebo to Evolocumab
- Biological · Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 16
- States / cities
- Anaheim, California • Mission Viejo, California • Westlake Village, California + 12 more
- Conditions
- Heterozygous Familial Hypercholesterolemia
- Interventions
- Evolocumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 12
- States / cities
- Farmington, Connecticut • Wilmington, Delaware • Iowa City, Iowa + 9 more
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Evolocumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- The Bronx, New York • Cincinnati, Ohio • Nashville, Tennessee
- Conditions
- Dyslipidemia
- Interventions
- Evolocumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 5,035 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 136 more
- Conditions
- Hypercholesterolemia
- Interventions
- Evolocumab, Placebo, Atorvastatin, Ezetimibe, Diet Only
- Biological · Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 905 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 33 more
- Conditions
- Dyslipidemia
- Interventions
- Evolocumab, Placebo, Background Statin Therapy
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 1,974 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 134
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 123 more
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- Evolocumab, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- New York, New York • Cincinnati, Ohio